A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2016
At a glance
- Drugs Sodelglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 20 May 2009 Additional locations identified as reported by ClinicalTrials.gov.
- 22 Jan 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.